Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Supernus Pharmaceuticals Q4 2023 Adj EPS $0.39 Misses $0.55 Estimate, Sales $164.31M Beat $155.03M Estimate

Author: Benzinga Newsdesk | February 27, 2024 05:30pm

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.55 by 29.09 percent. The company reported quarterly sales of $164.31 million which beat the analyst consensus estimate of $155.03 million by 5.99 percent. This is a 1.80 percent decrease over sales of $167.33 million the same period last year.

Posted In: SUPN